Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :
(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).
(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with uveal melanoma | Other | High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. For enucleated patients, a blood sample is required according to the study schedule. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood test | Other | High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule : (i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines). (ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.
|
| Measure | Description | Time Frame |
|---|---|---|
| Description of the metastatic events and treatments in high risk UM patients and correlation to biomarkers | metastatic events and treatments reports correlation with their ocrresponding biomarquers | 120 months |
| Biological study (lymphocytes) | lymphocyte phenotype analysis with biological tests | 120 months |
| Biological study (ctDNA) | circulating tumor DNA analysis with biological tests | 120 months |
| Measure | Description | Time Frame |
|---|---|---|
| Biological samples prospective collection (ctDNA) | collection of biological samples (circulating tumor DNA analyses) | 120 months |
| Biological samples prospective collection (immune-monitoring analyses) |
Not provided
Inclusion Criteria:
Patient aged of 18 years or more.
Patient with uveal melanoma with high metastatic relapse risk defined as :
Completion of treatment of the primary tumor ≤ 2 months.
Patient able to comply with the schedule of visits and blood samples of the study.
Signed informed consent form or legal representative.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sophie Piperno-Neumann, MD | Contact | 01 44 32 46 72 | sophie.piperno-neumann@curie.fr | |
| Marie-Emmanuelle Legrier, PhD | Contact | 01 56 24 56 49 | drci.promotion@curie.fr |
| Name | Affiliation | Role |
|---|---|---|
| Sophie Piperno-Neumann, MD | Institut Curie | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Curie | Recruiting | Paris | 75005 | France |
Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.
Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.
Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
Not provided
Not provided
| ID | Term |
|---|---|
| D000098943 | Uveal Melanoma |
| ID | Term |
|---|---|
| D008545 | Melanoma |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
Not provided
Not provided
| ID | Term |
|---|---|
| D006403 | Hematologic Tests |
| D009682 | Magnetic Resonance Spectroscopy |
| ID | Term |
|---|---|
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
collection of biological samples (immune-monitoring analyses) with biological tests
| 120 months |
| Biological samples prospective collection (sequencing analyses) | collection of biological samples (sequencing analyses) with biological tests | 120 months |
| Comparison of clinical and imaging data (MRI) | Comparison of imaging data (MRI) between the patients with and without identified biomarkers (biological tests) | 120 months |
| Comparison of clinical and imaging data (clinical data) | Comparison of clinical data between the patients with and without identified biomarkers (biological tests) | 120 months |
| Univariate analysis of the prognostic value of identified biomarkers | prognostic value of identified biomarkers analysis with biological tests | 120 months |
| Multivariate analysis of the prognostic value of identifies biomarkers adjusted for clinical and imaging data | Multivariate analysis of the prognostic value of identifies biomarkers (biological tests) adjusted for clinical (medical patients records) and imaging data (MRI) | 120 months |
| Analysis of discordant cases regarding genomic/tumor size prognostic factors and outcomes | Analysis of discordant cases regarding genomic/tumor size prognostic factors | 120 months |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D014604 | Uveal Neoplasms |
| D005134 | Eye Neoplasms |
| D009371 | Neoplasms by Site |
| D005128 | Eye Diseases |
| D014603 | Uveal Diseases |
| D013057 | Spectrum Analysis |
| D002623 | Chemistry Techniques, Analytical |